Molecular radiobiology

Regulation of O$_2$ consumption by the PI3K and mTOR pathways contributes to tumor hypoxia

Catherine J. Kelly, Kamila Hussien, Emmanouil Fokas, Pavitra Kannan, Rebecca J. Shipley, Thomas M. Ashton, Michael Stratford, Natalie Pearson, Ruth J. Muschel

*Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford; †Department of Mechanical Engineering, University College London; ‡Mathematical Institute, University of Oxford, UK

**Corresponding author.
E-mail address: ruth.muschel@gmail.com (R.J. Muschel).

**Article info

Article history:
Received 11 September 2013
Received in revised form 10 January 2014
Accepted 9 February 2014
Available online 13 March 2014

Keywords:
PI3K
mTOR
Oxidative metabolism
Hypoxia
Reoxygenation

**Abstract

Background: Inhibitors of the phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) pathway are currently in clinical trials. In addition to antiproliferative and proapoptotic effects, these agents also diminish tumor hypoxia. Since hypoxia is a major cause of resistance to radiotherapy, we sought to understand how it is regulated by PI3K/mTOR inhibition.

Methods: Whole cell, mitochondrial, coupled and uncoupled oxygen consumption were measured in cancer cells after inhibition of PI3K (Class I) and mTOR by pharmacological means or by RNAi. Mitochondrial composition was assessed by immunoblotting. Hypoxia was measured in spheroids, in tumor xenografts and predicted with mathematical modeling.

Results: Inhibition of PI3K and mTOR reduced oxygen consumption by cancer cell lines is predominantly due to reduction of mitochondrial respiration coupled to ATP production. Hypoxia in tumor spheroids was reduced, but returned after removal of the drug. Murine tumors had increased oxygenation even in the absence of average perfusion changes or tumor necrosis.

Conclusions: Targeting the PI3K/mTOR pathway substantially reduces mitochondrial oxygen consumption thereby reducing tumor hypoxia. These alterations in tumor hypoxia should be considered in the design of clinical trials using PI3K/mTOR inhibitors, particularly in conjunction with radiotherapy.

© 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 72–80 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Genetic alterations that lead to aberrant activation of the PI3K and mTOR pathways are among the most frequent in cancers of all types [8,40]. PI3K/mTOR pathway signaling promotes a plethora of oncogenic cellular functions including growth and cell survival. As a result, a variety of pharmacologic agents have been developed to inhibit this pathway and are entering clinical trials [25].

In addition to reducing tumor proliferation and survival, we and others have shown that inhibitors of the PI3K pathway greatly diminish tumor hypoxia [14,38,53], a characteristic feature of solid tumors which correlates with poorer prognosis, increased metastasis and resistance to therapeutic intervention, particularly radiotherapy (XRT) [18,33,34]. A variety of strategies to increase tumor oxygenation have been proposed in order to improve the outcome of XRT, including the inhalation of hyperoxic gases [20–23,42], and vascular normalization [10,19,41]. Poor local perfusion is a major contributor to hypoxia, resulting from the disorganized vasculature, increased interstitial pressures and transient vascular closures commonly found in cancer [50]. Inhibition of PI3K signaling results in improved vascular structure and perfusion [14,38], suggesting that vascular normalization plays a role in the observed reoxygenation. However, potential contributions of alterations in oxygen consumption have not been determined. Mathematical modeling of the roles of supply and demand in tumor oxygenation suggests that reduction of hypoxia is more likely to be accomplished by decreasing tumor oxygen consumption than by improvement of vascular supply [45].

Consistent with this idea, Gallego and colleagues have shown that treatment of some murine tumors with inhibitors of the Epidermal Growth Factor Receptor (EGFR) or with AsO$_3$ leads to decreased O$_2$ consumption and hence decreased hypoxia in experimental tumors correlating with enhanced efficacy of XRT [3,12]. The effects of inhibiting PI3K and mTOR on O$_2$ consumption and tissue oxygenation however, have not been similarly explored.

Here we report that pharmacological and genetic inhibition of PI3K and/or mTOR leads to diminished O$_2$ consumption in a panel of cell lines from different primary tumors. Using spheroid and
in vivo models, we found that tissue hypoxia was reduced even in the absence of vascular remodeling by pharmacological inhibition of PI3K/mTOR.

Methods

In vitro studies

The cell lines tested FaDu (human nasopharyngeal), EMT6 (mouse mammary carcinoma), HCT116 (human colorectal) and U87 (human glioma) were chosen because they form spheroids of sufficient size (~400–500 µm diameter) to become hypoxic. Spheroids generated using the liquid overlay technique of PI3K/mTOR.

Treatments

BEZ235 and BKM120 (Novartis Pharmaceuticals) and AZD8055 (#CT-A8055, ChemieTek) were dissolved in 0.1% DMSO. Control groups were treated with equal amounts of DMSO.

Cell transfections were performed by reverse transfection with Interferin (PolyPlus) using 5 nM short interfering RNA (siRNA) oligonucleotides for PI3K110α (#L-003018), p85β (#L-003021), mTOR (#L-003008) and non-targeting (#D-001810) from Dharmacon RNAi Technologies. Doses in tissue culture were chosen based on the lowest concentration to reduce pAKT repeatedly and by at least approximately 3-fold.

Immunoblotting

Antibodies were: pAKT (Ser-573 #9271, 1:1000), pmTOR (Ser-235 #2971, 1:500), pS6 ribosomal protein (Ser235/236 #4856, 1:1000), all Cell Signalling Technology in 5% Bovine Serum Albumin (BSA); Actin (mAb clone AC-15 #A1978, Sigma, 1:20,000 in 5% milk); citrate synthase (#CISY-11A, Alpha Diagnostic, 1:500 in 5% milk); OXPHOS complexes (#MS601, Mitosciences, 1:500 in milk); DAB Peroxidase substrate kit (SK-4100, VectorLabs) and DAB Peroxidase substrate kit (SK-4100, VectorLabs). Images acquired with a Nikon Eclipse 90i with a Hamamatsu ORCA-ER camera. A mask was created for each spheroid using the Hoechst image, prior to measuring the average pixel intensity per spheroid in the background-subtracted EF5 image using ImageJ [1].

To assess signaling inhibition in spheroids, sections were stained with anti-pAKT antibody using Immpress™ reagent kit (MP-7401, VectorLabs) and DAB Peroxidase substrate kit (SK-4100, VectorLabs). Images acquired with a Nikon Eclipse E800 were analyzed for 3,3’-Diaminobenzidine (DAB)-positive pixels semi-automatically using a method described previously [6].

Statistical analysis

Quantitative data were expressed as means ± 95% Confidence Interval. One-way ANOVAs, followed by the Bonferroni post-test, were used to assess the differences among various treatments with Prism 5 (GraphPad Software Inc.), unless otherwise stated.

Mathematical modeling

For simulation of in vivo O2 consumption, 2D vascular networks were generated stochastically [37], using vessel parameter distributions (vessel length, diameter and branching angle) obtained from ex vivo data [14]. The resulting coupled blood flow and O2 transport problem was solved using code available via Dr. Seccombe’s website (www.physiology.arizona.edu/people/secomb/greens). A representative base O2 consumption rate of 1.5 cm3/100 cm3/min was used [46].

In vivo studies

All animal experiments were carried out in accordance with UK Home Office regulations. FaDu cells bearing a HRE-luc reporter (Cignal Lenti HIF Reporter luciferase (SABiosciences)), for hypoxia were described and validated previously [38]. 1 × 106 cells were inoculated subcutaneously in athymic nude mice. Mice were divided into cohorts of n = 4 mice per cohort. Drug administration by oral gavage was initiated once tumors reached 100 mm3 volume, as determined using calipers. Tumors were treated for 7 days with BEZ235 at 0, 20 or 30 mg/kg in NMP/PEG300 (Novartis Pharmaceuticals, Basel, Switzerland). Decreases in hypoxia were seen at 3 days with maximal effects by 5–7 days. We failed to observe effects at earlier times. Thus we used 7 days for these experiments. Imaging of hypoxia and perfusion was carried out as previously described [38]. Before sacrifice EF5 was administered as previously described [38]. Tumor tissue was fixed and stained for EF5 and Ki-67. Images were acquired using a Nikon Eclipse E800 microscope with a Nikon DMAX1200 digital camera and measured with ImageJ.
Results

**PI3K/mTOR inhibition reduced tumor cell oxygen consumption**

The O$_2$ consumption rate (OCR) of cancer cell monolayers (normalized to cell number) was reduced after 24 h treatment with the Class I PI3K inhibitor BKM120 or with the dual PI3K/mTOR inhibitor BEZ235 (Fig. 1A, \( P < 0.01 \), one-way ANOVA and Supplemental Fig. 1B). A trend for reduced OCR was evident within 5 h of treatment with either inhibitor although this was not uniformly significant (Supplemental Fig. 1C). Functional inhibition of PI3K was demonstrated by dose-dependent reduction in AKT phosphorylation at 24 h (Fig. 1C). Both drugs also reduced the phosphorylation of mTOR and S6. BEZ235 is a direct inhibitor of mTOR.

**Fig. 1.** Inhibition of PI3K and mTOR activities reduces oxygen consumption in vitro. (A) Effect of dual PI3K/mTOR inhibitor BEZ235 and single Class I PI3K inhibitor BKM120 on cellular oxygen consumption rate (OCR). FaDu, EMT6, HCT116 and U87 cells were treated as indicated for 24 h. Total cellular oxygen consumption rate (OCR) was calculated in \( n = 12 \) wells. Data shown are representative of three independent experiments. (B) Immunoblotting confirmed reduction in signaling through the PI3K/mTOR pathway in monolayers treated with BEZ235 or BKM120 for 4 h (12 h and 24 h for HCT116 and U87 respectively). (C) Treatment for 24 h with the mTOR inhibitor AZD8055 decreased OCR. (D) Immunoblotting for pS6 confirmed AZD8055 reduced OCR. (E, F) Immunoblotting for pAKT and pmTOR in transfected cells show reduced signaling through the PI3K/mTOR pathway. (G) FaDu cells transfected with PI3K p110$\alpha$, p85$\beta$ or mTOR siRNA exhibit reduced mitochondrial OCR compared with those transfected with NT siRNA. All data points represent mean ± 95% Confidence Interval. One-way ANOVAs were performed with Bonferroni-corrected post t-tests comparing treated to DMSO-treated control samples. \( P < 0.01 \). Data shown are representative of three independent experiments.
However since mTOR is also a downstream target of PI3K, the decrease in pmTOR and pS6 seen with BKM120, a specific PI3K inhibitor is not unexpected. Thus the use of the specific PI3K inhibitor BKM120 does not preclude mTOR as a target. mTOR can also feedback onto PI3K and AKT pathways. The OCR in cells treated with the direct mTOR inhibitor AZD8055 was also reduced in a dose-dependent fashion (Fig. 1C and D). Treatment with rotenone and antimycin A, which block mitochondrial electron transport, inhibited the O$_2$ consumption by these cells (FaDu 82.9%; EM86 91.1%; HCT116 79%; U87 75%) showing that mitochondrial respiration accounted for the preponderance of O$_2$ consumption. Thus treatment with PI3K/mTOR inhibitors diminished the mitochondrial O$_2$ consumption in a variety of cancer cells.

In addition, we reduced signaling in FaDu cells by genetic means (Fig. 1E and F). RNAi against PI3K 85 (regulatory domain) and PI3K 110z (catalytic domain) reduced their respective protein levels and depressed signaling as measured by pAKT and pS6 levels. RNAi against mTOR reduced its protein levels and also depressed the signaling through S6. O$_2$ consumption in PI3K and mTOR-silenced cells was reduced by 25–30% compared to the non-targeted control (Fig. 1G). Thus genetic interference with the PI3K signaling pathway also reduced O$_2$ consumption as did pharmacological inhibition.

The PI3K/mTOR pathway is a promoter of glycolytic metabolism [13,52]. In the cell lines tested, treatment with BKM120 reduced glycolysis. However, BEZ235 inhibited glycolysis in some cell lines, but not in others (Supplementary Fig. 1D). Because mitochondrial oxygen consumption can be limited by substrate availability through glycolysis, glucose-free medium supplemented with pyruvate and glutamine was used for the above OCR measurements.

PI3K/mTOR inhibition reduce mitochondrial function, not protein

We examined the possibility that a reduction in mitochondrial mass might contribute to decreased O$_2$ consumption. However, the levels of citrate synthase, a component of the Krebs cycle frequently used to monitor mitochondrial mass, remained unchanged after treatment with either inhibitor (Fig. 2A and Supplementary Fig. 2A). Levels of electron transport chain (ETC) complexes I, IV and V (ATP synthase) increased in the mitochondrial fraction of FaDu cells treated with BEZ235 or BKM120 compared to the control (Fig. 2B), confirming that the mitochondrial amounts were not reduced.

We next looked at the effect of BEZ235 and BKM120 on mitochondrial bioenergetics. In a normally functioning cell, the rate of cellular O$_2$ consumption (as shown in Fig. 1A) is determined by the activity of the electron transport chain (ETC) and the rate of ATP production, with these processes ‘coupled’ via the proton gradient (Fig. 2C). In addition to this, proton leakage and non-mitochondrial also contribute. To assess the specific contributions of ATP synthesis and ETC activity to altered O$_2$ consumption, we compared respiration in both the coupled and uncoupled states through sequential addition of oligomycin (an ATP synthase inhibitor) and FCCP (which dissipates the proton gradient) (Fig. 2D). Coupled respiration was reduced by BEZ235 or BKM120 treatment in all cell lines (Fig. 2E). However, as coupled respiration is dependent on the supply of electrons from the ETC, this does not in itself show that the reduction is dependent on ATP synthase activity. Hence it is necessary to also consider uncoupled respiration, which reflects ETC activity. Treatment with BEZ235 or BKM120 reduced uncoupled respiration in the human cells lines (FaDu, HCT116 and U87), although the effect was smaller than that observed for coupled respiration (Fig. 2F). Thus both coupled and uncoupled respiration are inhibited by PI3K/mTOR inhibition.

Decreased oxygen consumption corresponds to a substantial improvement in 3D oxygenation

To evaluate whether the results in monolayers could translate to a 3D tissue environment, we examined hypoxia within spheroids. Inhibition of PI3K in FaDu and EM86 spheroids was demonstrated by reduction of pAKT staining after drug treatment (Fig. 3A and B). Spheroids of 450–500 µm diameter were treated for 24 or 48 h with either DMSO, BEZ235 (50 nM) or BKM120 (5 µM). Hypoxia that was evident in the control spheroids, as indicated by EF5 staining, was reduced in spheroids treated with either BEZ235 or BKM120 (Fig. 3C and D). These spheroids were smaller than the controls (Supplementary Fig. 3A), suggesting proliferation was affected by the inhibitors. As EF5 binds only in viable cells, there was the possibility that cell death accounted for the reduction in signal. To examine this possibility, the spheroids were returned to drug-free medium after 24 h of drug treatment. Hypoxia recurred, demonstrating viability with the exception of BKM120-treated FaDu spheroids. (Fig. 3C and E) (p < 0.01, two-way ANOVA). Dose-dependent reductions in hypoxia were also observed in HCT116 spheroids (Supplementary Fig. 3B). Thus decreased O$_2$ consumption due to PI3K/mTOR inhibition leads to decreased hypoxia in spheroids.

Reduction in hypoxia in treated tumors is consistent with impaired oxygen consumption

The findings using spheroids presented above support the hypothesis that reduction of oxygen consumption due to PI3K/mTOR inhibition would result in a reduction of tumor hypoxia in vivo. Additionally since spheroids are avascular, their use bypasses the complexities of the tumor vasculature. To evaluate the effect that reduced O$_2$ consumption might have in the context of abnormal vasculature, we used a mathematical modeling approach developed by Secomb et al. [46]. 2D and 3D vascular networks were generated in silico, derived from serial confocal images of xenografts from the FaDu cell line [14]. Simulations of blood flow through these vascular networks were combined with factors for the rate of O$_2$ diffusion and O$_2$ consumption by the surrounding tissue. Fig. 3F and G show oxygen distributions in one such vascular network using two different rates of O$_2$ consumption (maximum and 55% of maximum), the latter observed in FaDu cells treated with 100 nM BEZ235. Using this model we calculated the mean hypoxic fraction from 10 different vascular networks observed in FaDu tumors across a range of decrements in O$_2$ consumption rates (Fig. 3H). A decrease of 20% in oxygen consumption would be predicted to decrease the mean hypoxic fraction by one-third, based on this model. Thus smaller reductions of O$_2$ consumption than the maximal observed in the monolayer would be predicted to be medically significant.

To test our predictions, we treated mice bearing FaDu HRE-Luc xenografts with BEZ235 at two different doses (20 mg/kg and 30 mg/kg). Both doses significantly reduced the luciferase signal compared to the untreated tumors (Fig. 4A). Reduction in hypoxia was confirmed through EF5 staining (Fig. 4B). We have previously demonstrated that administration of 20 mg/kg BEZ235 results in a greater density of normalized blood vessels and increased perfusion in FaDu xenografts [14]. However PI3K inhibition with BEZ235 or other drugs at higher doses has been reported to lead to blood vessel destruction in tumors [14,17,24]. Tumors treated with 30 mg/kg BEZ235 had no increase in perfusion compared to the control (Fig. 4C), but still demonstrated a substantial reduction in hypoxia. Both doses led to greater than 5-fold reduction of pAKT or pS6 staining (Fig. 4D). However the lower dose did not reduce proliferation of the tumor cells while the higher dose had a strong
antiproliferative effect on the tumor cells without noticeable histological evidence of necrosis (Fig. 4D, quantified in Fig. 4E). Reduced proliferation at the higher, but not the lower, dose was reflected in growth curves (Supplemental Fig. 4). Both doses resulted in decreased hypoxia. Treatment of mice with tumors with BEZ235 at the higher dose led to decreased hypoxia despite no change in...
Fig. 3. Hypoxia is reduced in a 3D spheroid model and is predicted to decline in vivo. (A) EMT6 and FaDu spheroids were treated for 24 h with BEZ235 or BKM120, prior to fixation and sectioning. Sections were DAB-stained for pAKT (Ser473) expression. Representative images are shown for BEZ235 (50 nM) and BKM120 (5 μM). (B) The percentage of DAB-positive pixels in the viable region of the spheroid was reduced with all treatments. (C) Spheroids were treated with 50 nM BEZ235 or 5 μM BKM120 for 24 h, 48 h or 24 h followed by 24 h incubation in drug-free medium (24 h + wash). Hypoxia was assessed by staining central spheroid sections for EF5 (red) with Hoechst as a counterstain (blue). Data shown are representative of two independent experiments, n = 10 spheroids. (D) Mean EF5 fluorescence in spheroids treated for 24 h was reduced in both cell lines tested. (E) To assess whether hypoxia was recoverable, mean EF5 fluorescence in spheroids treated for 24 h was compared with that in spheroids treated for either 48 h or 24 h followed by the 24 h wash in drug-free medium. In cells treated with BEZ235, the 24 h wash period led to a return of the hypoxia signal. (F and G) Simulated distribution of oxygen partial pressure (mmHg) in a representative 1497 μm x 1482 μm vascular network derived from ex vivo samples where oxygen consumption was either 100% (F) or 55% (G) of base level. Highly oxygenated regions are in red, scaling down to poorly oxygenated regions in blue. (H) Average hypoxic fraction (defined as <10 mmHg) calculated across 10 example networks as in F as a function of varying oxygen consumption. All data points represent mean ± 95% Confidence Interval. One-way ANOVAs were performed with Bonferroni-corrected post t-tests. *P < 0.01.
BEZ235 reduces hypoxia in vivo in the absence of vascular normalization. Xenograft tumors from the FaDu cell line with a stably expressed hypoxia-dependent luciferase signal were grown in athymic nude mice. Mice were divided into cohorts of \( n = 4 \) mice per cohort. Tumors were treated for 7 days with BEZ235 at 0, 20 or 30 mg/kg. (A) Hypoxia was monitored by bioluminescent imaging of the luciferase signal. Representative images and hypoxia measurements from FaDu tumors at day 7 treated with BEZ235 at doses indicated show that the hypoxia signal is reduced with BEZ235 treatment. (B) Immunostaining for EF5 (green) in FaDu tumors independently confirmed the reduction in hypoxia (10x magnification). (C) Perfusion as depicted by microbubbles (orange signal), was evaluated in the entire tumor at day 7 after treatment with BEZ235 as indicated. Increased perfusion, indicative of vascular normalization, was present in tumors treated with 20 mg/kg, but not 30 mg/kg, BEZ235. Columns, mean; bars, 95% CI. (D) Evaluation of the effects of BEZ235 on pAKT, pS6 and the proliferation marker Ki-67 in FaDu tumors. Sections were stained with the indicated antibodies. Both doses of BEZ235 reduced signaling through the PI3K/mTOR pathway, but only the higher dose (30 mg/kg) of BEZ235 reduced proliferation. Magnification as shown in image (E). Columns, mean; bars, 95% CI. *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \), over vehicle-treated control.
overall perfusion consistent with the hypothesis that BEZ235 induced decreased hypoxia due to reduced O₂ consumption independent of alterations in perfusion.

Altogether, our findings indicate that alterations to cellular O₂ consumption could have a significant impact on tumor hypoxia, in agreement with previous in vivo observations [3,12].

Discussion

In this study we show that pharmacological or genetic inhibition of the PI3K/mTOR pathway reduces mitochondrial O₂ consumption in a panel of cancer cell lines. As a consequence, pharmacological inhibition of PI3K reduces hypoxia in spheroids and tumor xenographs.

Several groups including our own have found that PI3K inhibition can lead to vascular normalization, correlating with decreased hypoxia [14,38,43]. However, our findings here suggest that reducing cellular O₂ consumption through PI3K inhibition can additionally have a significant effect on hypoxia. It is likely that in vivo changes in hypoxia mediated by PI3K inhibition result from a synergy of the increased blood flow and reduced respiration.

In agreement with our findings, reduced O₂ consumption after direct inhibition of the PI3K/mTOR pathway [26,32,33], or after the withdrawal or inhibition of growth factors which act via the pathway has been previously reported [3,32,49]. However there is no consensus on how the pathway regulates oxidative respiration. PI3K/AKT/mTOR signaling can be hypothesized to enhance respiration through multiple mechanisms, including substrate generation, metabolite transport across the mitochondrial membrane and activity of the mitochondrial machinery. While increased mitochondria biogenesis is one means of generating increased oxidative metabolism, we failed to detect evidence of a decrease in overall mitochondria mass in treated cells with unchanged levels of citrate synthase and increased levels of mitochondrial complexes. However we did not examine mitochondrial numbers, morphology or location. In our measurements of oxygen consumption, excess pyruvate and glutamine were used to saturate the reaction, removing substrate limitations. However, substrate availability could still play a role in spheroids or in vivo, particularly through glycolysis. Amounts of the glucose transporter GLUT1 may be reduced after PI3K/AKT/mTOR inhibition [7,11,36,39,48]. Localization of hexokinase II to the mitochondria where it couples glycolysis to ATP synthesis, enhancing glycolytic flux, is also reduced by mTOR and AKT inhibition [2,4,31].

Accessibility of ADP and ATP to the mitochondrial matrix could be a point of regulation of mitochondrial oxygen consumption as well. ADP and ATP enter the mitochondria through the outer mitochondrial membrane via the voltage dependent anion channel (VDAC). ADP/ATP flow to and from mitochondrial ATP synthesis is essential to relieve the proton gradient set up by the ETC, enabling electron transport and O₂ consumption. Consistent with involvement of ADP/ATP transport or turnover, mitochondrial hyperpolarization, caused by a buildup of this gradient, has been reported in both AKT- and mTOR complex 2-deficient cells and after treatment with the mTOR inhibitor rapamycin [4,35]. It is possible that the PI3K/mTOR pathway regulates VDAC. Localization of mTOR and its target Ser473-phosphorylated AKT to VDAC1 are increased after growth factor stimulation [4] and conductance through the channel is negatively regulated by the AKT target glycogen synthase kinase 3β (GSK3β) [28,47,5].

Finally, Ff1, Ff2- ATP synthase may be regulated by PI3K/AKT/mTOR signaling. Active AKT interacts with ATP synthase [5,54] and its subunits contain consensus sequences for AKT binding [26]. In Pten−/− cells, activated AKT binds the α and β subunits of ATP synthase to stimulate activity [26]. Activated AKT may therefore directly control the rate of ATP synthesis, and therefore oxygen consumption, through phosphorylation of ATP synthase. “Further work will be needed to elucidate the biochemical mechanisms that lead to alterations in oxygen metabolism and to determine potential relationships to proliferation. Of course cell death itself could decrease oxygen consumption. We attempted to control for toxicity through normalization for cell death in tissue culture, by noting that the effect is reversible in spheroids and that in vivo at the lower dose the extent of proliferation in similar to controls.”

Decreased hypoxia in tumors treated with PI3K/mTOR inhibition would be expected to lead to increased sensitivity to radiation. This expectation is confirmed since pharmacological inhibition of PI3K, mTOR and dual PI3K/mTOR inhibition have all been reported to increase sensitivity to DNA damaging agents in murine cancer models [15,27,30,44]. We showed enhanced tumor growth delay in response to radiation after treatment with BEZ235 correlating with decreased hypoxia. However it is more difficult to determine to what extent alleviation of hypoxia accounts for these results, because these inhibitors also sensitize cells to DNA damage underoxic conditions. Inhibition of PI3K reduces DNA damage repair, but BEZ235 also has off-target effects of inhibition of ATR and DNA-PK [29]. Fokas et al. attempted to separate the effects on tumor oxygenation from cell-specific effects by administering the drug BEZ235 immediately before tumor radiation, when it still altered tumor signaling but before the more prolonged changes of hypoxia associated with extended preincubation had occurred. This study however showed a substantial sensitization resulting from the addition of BEZ235 to radiation. Approximately 1/3 of the effect of sensitization resulted, suggesting that both alterations in hypoxia and direct effects on tumor cell sensitization are at work [14]. Nonetheless both mechanisms could contribute to radiosensitization which could be of clinical significance.

In this study, we have demonstrated for the first time that inhibition of the PI3K/mTOR pathway reduces cellular oxygen consumption and leads to reoxygenation of tumor tissue independent of vascular effects. In light of our findings, ongoing clinical trials with PI3K/mTOR pathway inhibitors are likely to be having substantial effects on tumor hypoxia. Because hypoxia greatly reduces the efficacy of radiotherapy a combination of radiation therapy with PI3K/mTOR inhibition may be beneficial.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.radonc.2014.02.007.

References


